Here are five takeaways:
1. Companies involved in ZeroTo510’s Executive in Residence program will now received guidance from Smith & Nephew executives about sales and product development.
2. Companies who previously went through the acceleration are still able to take part in the Executive in Residence program.
3. For the last five years, ZeroTo510 has guided medical device companies through the FDA clearance process.
4. Smith & Nephew began working with the Executive in Residence program in June.
5. Kelley Grusin, senior director of product development at Smith & Nephew, said, “To be immersed in the ZeroTo510 entrepreneurial and acceleration environment will in turn benefit our team and expand their knowledge from a unique business development perspective.”
More articles on devices and implants:
Global bone growth stimulator market to hit $3.9B by 2025
ReNetX Bio initiates financing round for spinal cord injury technology trail: 7 highlights
Tissue Regenix proposes acquisition of CellRight Technologies: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
